Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00180
|
|||||
| Drug Name |
Levetiracetam
|
|||||
| Synonyms |
(-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; Etiracetam levo-isomer; Etiracetam, S-isomer; Keppra; Keppra (TN); Keppra XR; Keppra, Keppra XR),Levetiracetam; L-059; Levetiracetam [INN]; Levetiracetamum [INN-Latin]; Levetiractam; Leviteracetam; SIB-S1; Torleva; UCB-22059; UCB-L 059; UCB-L059; Ucb L060
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Epilepsy [ICD11:8A6Z] | Approved | [1] | |||
| Therapeutic Class |
Anticonvulsants
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C8H14N2O2
|
|||||
| Canonical SMILES |
CCC(C(=O)N)N1CCCC1=O
|
|||||
| InChI |
InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
|
|||||
| InChIKey |
HPHUVLMMVZITSG-LURJTMIESA-N
|
|||||
| CAS Number |
CAS 102767-28-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 170.21 | Topological Polar Surface Area | 63.4 | ||
| Heavy Atom Count | 12 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 2 | |||
| XLogP |
-0.3
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10043
,103397964
,11039358
,113863233
,11528730
,118048597
,118317474
,12013706
,121361595
,124658926
,124757185
,124801236
,125163989
,125307963
,126629740
,126645371
,126655872
,128093760
,131293132
,134338679
,135017078
,135610154
,135684175
,135692116
,135697608
,136375572
,15321884
,15321885
,26719810
,39317891
,46386557
,48416166
,49681695
,49830155
,50363327
,56310923
,56312936
,56312991
,56313270
,57359126
,68530790
,7847774
,7979767
,90341134
,91614180
,92308297
,92308916
,92713787
,93166400
,99437106
|
|||||
| ChEBI ID |
ChEBI:6437
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Levetiracetam was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.